Abbott Laboratories Chairman and CEO Robert B. Ford purchased 18,800 shares of common stock. The transaction totaled approximately $2 million.
Ford acquired the shares at a weighted average price of $107.1259. A Form 4 filing with the SEC confirmed the transaction date as January 23, 2026.
The insider purchase followed a significant drop in Abbott’s stock price. The decline occurred after the company announced fourth-quarter 2025 earnings on January 22.
Abbott missed revenue expectations for the quarter. Weakness in the Nutrition segment drove the post-earnings sell-off.
Investors often interpret the substantial purchase as a bullish signal. This suggests leadership believes the stock is undervalued. The purchase signals confidence in the company’s long-term prospects.